Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis

Main Article Content

Tiffany Mayo
April W Armstrong
Leon Kircik
Jonathan Silverberg
Andrew Blauvelt
Ben Esdalie
Shannon Schneider
Thomas Mark
Melinda Gooderham
Andrew F Alexis


tralokinumab, atopic dermatitis, moderate to severe, efficacy, safety




1. Weidinger S, Novak N. Lancet. 2016;387(10023):1109-1122.

2. Kaufman B, et al. Exp Dermatol 2018; 27: 340-357.

3. Blauvelt A, et al. J Am Acad Dermatol. 2022;S0190-9622(22)02345-3

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>